cepharanthine has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ai, N; Dang, Y; Ge, W; Head, SA; Kwon, HJ; Li, RJ; Liu, JO; Liu, Y; Lyu, J; Shim, JS; Wu, C; Yang, C; Yang, EJ; Zhang, B | 1 |
| Ferdous, T; Harada, K; Itashiki, Y; Mano, T; Mori, Y; Takii, M; Ueyama, Y | 1 |
2 other study(ies) available for cepharanthine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growth.
Topics: Angiogenesis Inhibitors; Animals; Animals, Genetically Modified; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzylisoquinolines; Cell Growth Processes; Cholesterol; Cisplatin; Drug Synergism; Human Umbilical Vein Endothelial Cells; Humans; Lysosomes; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zebrafish | 2017 |
Cepharanthine inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing expression of vascular endothelial growth factor and interleukin-8.
Topics: Animals; Antineoplastic Agents, Phytogenic; Benzylisoquinolines; Blotting, Western; Carcinoma, Squamous Cell; Cell Movement; Cell Proliferation; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunohistochemistry; Interleukin-8; Mice; Mice, Nude; Mouth Neoplasms; Neovascularization, Pathologic; NF-kappa B; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |